Versteegen Pauline, Berbers Guy A M, Smits Gaby, Sanders Elisabeth A M, van der Klis Fiona R M, de Melker Hester E, van der Maas Nicoline A T
National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, 3720 BA, Netherlands.
Wilhelmina Children's Hospital, Department of Paediatric Immunology and Infectious Diseases, Lundlaan 6, 3584 EA Utrecht, Netherlands.
Lancet Reg Health Eur. 2021 Sep 6;10:100196. doi: 10.1016/j.lanepe.2021.100196. eCollection 2021 Nov.
Pertussis is a respiratory disease and still endemic despite high vaccination coverage. In the Dutch national immunisation programme (NIP) whole cell pertussis (wP) priming vaccines for infants were replaced by acellular pertussis (aP) priming vaccines in 2005. Serosurveillance gives the opportunity to objectively monitor effects of changes in the NIP on infection prevalence and vaccine response in the population over time.
For this population-based cross-sectional serosurvey a representative sample of Dutch residents (0-89 years) was drawn in 2016/2017. Primary outcome was the percentage of participants with pertussis toxin specific antibody concentrations ≥ 100 IU/ml as an indicator of recent infection, and to identify groups possibly more vulnerable to pertussis infection. Percentages were compared with previous results from 2006/2007.
In total 7621 persons were included in the analysis. An increase in recent infections from 3•5% to 5•9% was found in the population from 7 years and older (n=6013) in 2016/2017 compared with 2006/2007. Most noteworthy increase was seen in 12-18-year-olds who were wP primed and aP boosted.
Infection prevalence is still increasing in the Netherlands inducing a risk of pertussis disease in vulnerable (age) groups. Delaying the preschool booster might prolong the period of protection during primary school and thereby possibly protect younger siblings. Extra boosters might be considered for risk populations like older adults and people with (pulmonary) co-morbidities, since they have higher chances of complications and hospitalisation.An unedited Dutch translation of the abstract is available in : Nederlandse samenvatting.
The Dutch Ministry of Health, Welfare, and Sport.
百日咳是一种呼吸道疾病，尽管疫苗接种覆盖率很高，但仍然流行。在荷兰国家免疫规划（NIP）中，2005年婴儿用的全细胞百日咳（wP）初种疫苗被无细胞百日咳（aP）初种疫苗所取代。血清学监测使我们有机会客观地监测NIP变化对人群中感染流行率和疫苗反应的长期影响。
在2016/2017年，从荷兰居民（0 - 89岁）中抽取具有代表性的样本进行基于人群的横断面血清学调查。主要结果是百日咳毒素特异性抗体浓度≥100 IU/ml的参与者百分比，作为近期感染的指标，并确定可能更容易感染百日咳的群体。将这些百分比与2006/2007年的先前结果进行比较。
共有7621人纳入分析。与2006/2007年相比，2016/2017年7岁及以上人群（n = 6013）中近期感染率从3.5%上升至5.9%。最显著的上升出现在接受wP初种和aP加强接种的12 - 18岁人群中。
荷兰的感染流行率仍在上升，这在易感（年龄）群体中引发了百日咳疾病的风险。推迟学龄前加强接种可能会延长小学期间的保护期，从而有可能保护年幼的兄弟姐妹。对于老年人和患有（肺部）合并症等风险人群，可能需要考虑额外的加强接种，因为他们出现并发症和住院的几率更高。摘要的未经编辑的荷兰语译文可在：Nederlandse samenvatting中获取。
荷兰卫生、福利和体育部。
Zotero 插件